Teva Pharmaceutical Industries LTD 10-Q quarterly reports

Teva Pharmaceutical Industries Limited announced amendments to its deposit agreement and the termination of its American Depositary Shares (ADS) program, with ordinary shares to be directly listed on the NYSE.

Teva Pharmaceutical Industries Limited reported a significant turnaround in Q3 2025, achieving net income and operating profit, driven by strong U.S. segment performance and substantial debt reduction.

Teva Pharmaceutical Industries Limited announced a significant increase in operating income and net income for the second quarter of 2025, driven by robust performance in its U.S. segment and strategic debt management, despite a slight revenue decrease in local currency terms.

Teva Pharmaceutical Industries reports a 2% increase in revenue for Q1 2025, driven by growth in AUSTEDO, generics, and AJOVY, while progressing with its Pivot to Growth strategy.

Teva Pharmaceutical Industries reported a 13% increase in revenue for the third quarter of 2024, but also faced a significant goodwill impairment and increased legal expenses.

Teva Pharmaceutical Industries reports a 7% revenue increase in Q2 2024, but also records a significant goodwill impairment charge.

Teva Pharmaceutical Industries reported a net loss for the first quarter of 2024, while navigating strategic changes, debt repayments, and ongoing legal challenges.